EUVIMEDEUVIMED entdecken
Crossref

Initial Evaluation of Radioiodine Therapy Using Imaging for Long-term Prognosis in Thyroid Cancer: A Retrospective Study

Rieko Nakatani iD, Tadashi Watabe iD, Atsunori Fukuhara iD, Toru Takano iD, Takashi Kamiya iD, Hidetaka Sasaki iD, Hiroyuki Kurakami iD, Yukiko Nakata iD, Michio Otsuki iD, Yoh Hidaka iD, Iichiro Shimomura iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf568 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Rieko Nakatani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Suita 565-0871, Japan. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Radioactive iodine (RAI) is an established therapy for thyroid cancer (TC). The aim of this study was to evaluate the prognosis and disease characteristics based on initial RAI therapy using image findings.

Methods

We reviewed the clinical records of 290 TC patients who received initial therapeutic RAI therapy following total thyroidectomy for ablation and treatment between 2010 and 2021. Patients were classified into 3 groups based on the 131I whole-body scintigraphy (WBS) combined with morphological imaging records: non-DM, RAI-non-avid DM, and RAI-avid DM. Progression-free survival (PFS) and overall survival were assessed in each group. Normalized indices were calculated automatically using dedicated software for each patient on WBS. 131I-avid lesions were defined as areas with uptake exceeding the mean + 2 SDs of the reference regions of interest placed at the head-cervical, thoracic, and abdominal-pelvis regions, Watabe proposed.

Results

The 5-year and 7-year survival rates for the non-DM, RAI-non-avid DM, and RAI-avid DM groups were 98% to 95%, 86% to 78%, and 82% to 82%, respectively. Average count of 131I-avid area was identified as a significant prognostic factor for PFS, being independent of age, distant metastatic pattern, histological subtype, and T classification. Retreatment was preferably performed within 2 years after the initial RAI therapy, as this period appears to be critical for efficacy. Additionally, the site of metastases was a strong prognostic determinant.

Conclusion

Precise imaging evaluation of the initial RAI therapy may help predict the prognosis during the first 5 years, contributing to more effective comprehensive treatment approaches for long-term management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iodine RadioisotopesThyroid NeoplasmsHumansFemaleRetrospective StudiesMaleMiddle AgedPrognosisAdultThyroidectomyAgedWhole Body ImagingYoung AdultSurvival RateFollow-Up StudiesRadionuclide ImagingAdolescent

Stichwörter der Autor:innen

radioactive iodine therapysodium/iodide symporterthyroid cancer

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Suita 565-0871, Japan.
  • Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
  • Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, The University of Osaka, Suita 565-0871, Japan.
  • Department of Adipose Management, Graduate School of Medicine, The University of Osaka, Suita 565-0871, Japan.
  • Department of Medical Technology, The University of Osaka Hospital, Suita 565-0871, Japan.
  • Department of Medical Innovation, The University of Osaka Hospital, Suita 565-0871, Japan.

ORCID-Profile: Rieko Nakatani, Tadashi Watabe, Atsunori Fukuhara, Toru Takano, Takashi Kamiya, Hidetaka Sasaki, Hiroyuki Kurakami, Yukiko Nakata, Michio Otsuki, Yoh Hidaka, Iichiro Shimomura

Zitieren

APA

Nakatani, R., Watabe, T., Fukuhara, A., Takano, T., Kamiya, T., Sasaki, H., Kurakami, H., Nakata, Y., Otsuki, M., Hidaka, Y., & Shimomura, I. (2025). Initial Evaluation of Radioiodine Therapy Using Imaging for Long-term Prognosis in Thyroid Cancer: A Retrospective Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf568

Vancouver

Nakatani R, Watabe T, Fukuhara A, Takano T, Kamiya T, Sasaki H, et al. Initial Evaluation of Radioiodine Therapy Using Imaging for Long-term Prognosis in Thyroid Cancer: A Retrospective Study. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf568

BibTeX
@article{Nakatani2025,
  author = {Nakatani, Rieko and Watabe, Tadashi and Fukuhara, Atsunori and Takano, Toru and Kamiya, Takashi and Sasaki, Hidetaka and Kurakami, Hiroyuki and Nakata, Yukiko and Otsuki, Michio and Hidaka, Yoh and Shimomura, Iichiro},
  title = {Initial Evaluation of Radioiodine Therapy Using Imaging for Long-term Prognosis in Thyroid Cancer: A Retrospective Study},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf568}
}
Kostenlos starten →